Related Experiment Video

Updated: Jul 20, 2026

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors
10:33

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors

Published on: October 26, 2015

Targeting cyclin D1, a downstream effector of INI1/hSNF5, in rhabdoid tumors

D Alarcon-Vargas1, Z Zhang, B Agarwal

  • 1Department of Molecular Genetics, Albert Einstein College of Medicine, New York, NY, USA.

Oncogene
|November 23, 2005
PubMed

Insights

Targeting cyclin D1, a key protein in rhabdoid tumors (RTs), shows promise. Therapies like N-(4-hydroxyphenyl)retinamide (4-HPR) and tamoxifen effectively inhibit RT growth by reducing cyclin D1 levels.

Area of Science:

  • Pediatric oncology
  • Molecular oncology
  • Cancer genetics

Background:

  • Rhabdoid tumors (RTs) are aggressive pediatric cancers lacking effective treatments.
  • INI1/hSNF5 tumor suppressor inactivation is common in RTs.
  • Cyclin D1 is a critical downstream target of INI1/hSNF5, essential for RT growth and survival.

Purpose of the Study:

  • To investigate the therapeutic potential of targeting cyclin D1 in RTs.
  • To evaluate the efficacy of N-(4-hydroxyphenyl)retinamide (4-HPR) and tamoxifen in RT treatment.

Main Methods:

  • RNA interference to downregulate cyclin D1 in rhabdoid cells.
  • Pharmacological treatment with 4-HPR and 4-hydroxy-tamoxifen (4OH-Tam) in vitro.
  • Assessment of cell cycle arrest, apoptosis, and growth inhibition.
  • In vivo studies using RT xenograft models.

Main Results:

  • RNA interference of cyclin D1 induced G1 arrest and apoptosis in rhabdoid cells.
  • 4-HPR alone induced G1 arrest and apoptosis.
  • Combination of 4-HPR and 4OH-Tam synergistically inhibited RT cell survival and growth, both in vitro and in vivo.
  • Drug combination effects correlated with cyclin D1 depletion.

Conclusions:

  • Downmodulation of cyclin D1 is a viable therapeutic strategy for RTs.
  • 4-HPR and tamoxifen demonstrate synergistic efficacy as chemotherapeutic agents for RTs.
  • Targeting cyclin D1 offers a novel treatment approach for these aggressive pediatric malignancies.

More Related Videos

Identification of Cyclin-dependent Kinase 1 Specific Phosphorylation Sites by an In Vitro Kinase Assay12:26

Identification of Cyclin-dependent Kinase 1 Specific Phosphorylation Sites by an In Vitro Kinase Assay

Published on: May 3, 2018

Identification of EGFR and RAS Inhibitors using Caenorhabditis elegans08:12

Identification of EGFR and RAS Inhibitors using Caenorhabditis elegans

Published on: October 5, 2020

Related Concept Videos

Positive Regulator Molecules01:45

Positive Regulator Molecules

To consistently produce healthy cells, the cell cycle—the process that generates daughter cells—must be precisely regulated.
Positive Regulator Molecules02:39

Positive Regulator Molecules

Mitotic cell division results in daughter cells that exactly resemble the parent cell. However, errors in the DNA replication or distribution of genetic material may lead to genetic mutations that may be passed down to every new cell formed from the resulting abnormal cell. Propagation of such mutant cells is restricted through checkpoint mechanisms present at different stages of the cell cycle. These checkpoints involve regulator molecules that either promote or demote cell cycle events.
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
M-Cdk Drives Transition Into Mitosis02:15

M-Cdk Drives Transition Into Mitosis

Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...
Inhibition of CDK Activity02:34

Inhibition of CDK Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...